Lenvatinib as a Promising Second-Line Therapy for Advanced Hepatocellular Carcinoma Post-Atezolizumab Plus Bevacizumab Failure: Insights from a Multicenter Phase II Trial

MedXY Editorial Team•Oct 28, 2025•news

Lenvatinib showed a median progression-free survival of 5.4 months in patients with advanced hepatocellular carcinoma (HCC) after progression on first-line atezolizumab plus bevacizumab (atezo-bev), surpassing the prespecified primary endpoint.
The objective response rate was 14.0%, with a high disease control rate of 82.0% and a median duration of response of 9.4 months, indicating durable clinical benefit.
The safety profile of lenvatinib was consistent with prior studies, with manageable toxicity including diarrhea, hypothyroidism, and anorexia; grade ≥3 adverse events occurred in 46% of patients.
This multicenter, prospective study provides the first robust clinical evidence supporting lenvatinib as a viable second-line treatment option post-atezo-bev failure in unresectable HCC.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Lenvatinib showed a median progression-free survival of 5.4 months in patients with advanced hepatocellular carcinoma (HCC) after progression on first-line atezolizumab plus bevacizumab (atezo-bev), surpassing the prespecified primary endpoint.
The objective response rate was 14.0%, with a high disease control rate of 82.0% and a median duration of response of 9.4 months, indicating durable clinical benefit.
The safety profile of lenvatinib was consistent with prior studies, with manageable toxicity including diarrhea, hypothyroidism, and anorexia; grade ≥3 adverse events occurred in 46% of patients.
This multicenter, prospective study provides the first robust clinical evidence supporting lenvatinib as a viable second-line treatment option post-atezo-bev failure in unresectable HCC.